403 related articles for article (PubMed ID: 32157757)
21. Neuronal cytoplasmic inclusions in tau, TDP-43, and FUS molecular subtypes of frontotemporal lobar degeneration share similar spatial patterns.
A Armstrong R
Folia Neuropathol; 2017; 55(3):185-192. PubMed ID: 28984110
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylated TDP-43 becomes resistant to cleavage by calpain: A regulatory role for phosphorylation in TDP-43 pathology of ALS/FTLD.
Yamashita T; Teramoto S; Kwak S
Neurosci Res; 2016 Jun; 107():63-9. PubMed ID: 26723245
[TBL] [Abstract][Full Text] [Related]
23. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
[TBL] [Abstract][Full Text] [Related]
24. How do the RNA-binding proteins TDP-43 and FUS relate to amyotrophic lateral sclerosis and frontotemporal degeneration, and to each other?
Baloh RH
Curr Opin Neurol; 2012 Dec; 25(6):701-7. PubMed ID: 23041957
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive assessment of TDP-43 neuropathology data in the National Alzheimer's Coordinating Center database.
Woodworth DC; Nguyen KM; Sordo L; Scambray KA; Head E; Kawas CH; Corrada MM; Nelson PT; Sajjadi SA
Acta Neuropathol; 2024 Jun; 147(1):103. PubMed ID: 38896163
[TBL] [Abstract][Full Text] [Related]
26. [Clinical and pathological spectrum of TDP-43 associated ALS].
Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.
Igaz LM; Kwong LK; Lee EB; Chen-Plotkin A; Swanson E; Unger T; Malunda J; Xu Y; Winton MJ; Trojanowski JQ; Lee VM
J Clin Invest; 2011 Feb; 121(2):726-38. PubMed ID: 21206091
[TBL] [Abstract][Full Text] [Related]
28. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.
Wegorzewska I; Bell S; Cairns NJ; Miller TM; Baloh RH
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18809-14. PubMed ID: 19833869
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.
Shenouda M; Zhang AB; Weichert A; Robertson J
Adv Neurobiol; 2018; 20():239-263. PubMed ID: 29916022
[TBL] [Abstract][Full Text] [Related]
30. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid.
Bigio EH; Wu JY; Deng HX; Bit-Ivan EN; Mao Q; Ganti R; Peterson M; Siddique N; Geula C; Siddique T; Mesulam M
Acta Neuropathol; 2013 Mar; 125(3):463-5. PubMed ID: 23378033
[No Abstract] [Full Text] [Related]
31. Phosphorylated and cleaved TDP-43 in ALS, FTLD and other neurodegenerative disorders and in cellular models of TDP-43 proteinopathy.
Arai T; Hasegawa M; Nonoka T; Kametani F; Yamashita M; Hosokawa M; Niizato K; Tsuchiya K; Kobayashi Z; Ikeda K; Yoshida M; Onaya M; Fujishiro H; Akiyama H
Neuropathology; 2010 Apr; 30(2):170-81. PubMed ID: 20102522
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in C9orf72 ALS/FTLD.
Khosravi B; Hartmann H; May S; Möhl C; Ederle H; Michaelsen M; Schludi MH; Dormann D; Edbauer D
Hum Mol Genet; 2017 Feb; 26(4):790-800. PubMed ID: 28040728
[TBL] [Abstract][Full Text] [Related]
33. TDP-43 and FUS: a nuclear affair.
Dormann D; Haass C
Trends Neurosci; 2011 Jul; 34(7):339-48. PubMed ID: 21700347
[TBL] [Abstract][Full Text] [Related]
34. RNA-binding proteins with prion-like domains in ALS and FTLD-U.
Gitler AD; Shorter J
Prion; 2011; 5(3):179-87. PubMed ID: 21847013
[TBL] [Abstract][Full Text] [Related]
35. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration.
Nishimura AL; Zupunski V; Troakes C; Kathe C; Fratta P; Howell M; Gallo JM; Hortobágyi T; Shaw CE; Rogelj B
Brain; 2010 Jun; 133(Pt 6):1763-71. PubMed ID: 20472655
[TBL] [Abstract][Full Text] [Related]
36. Structure of pathological TDP-43 filaments from ALS with FTLD.
Arseni D; Hasegawa M; Murzin AG; Kametani F; Arai M; Yoshida M; Ryskeldi-Falcon B
Nature; 2022 Jan; 601(7891):139-143. PubMed ID: 34880495
[TBL] [Abstract][Full Text] [Related]
37. An acetylation switch controls TDP-43 function and aggregation propensity.
Cohen TJ; Hwang AW; Restrepo CR; Yuan CX; Trojanowski JQ; Lee VM
Nat Commun; 2015 Jan; 6():5845. PubMed ID: 25556531
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS).
Vaca G; Martinez-Gonzalez L; Fernandez A; Rojas-Prats E; Porras G; Cuevas EP; Gil C; Martinez A; Martin-Requero Á
J Neurochem; 2021 Feb; 156(3):379-390. PubMed ID: 32628315
[TBL] [Abstract][Full Text] [Related]
39. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
[TBL] [Abstract][Full Text] [Related]
40. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
